Marc Iskowitz

Most recent articles by Marc Iskowitz

‘A chance to build’: Leo Tarkovsky details his move to Fingerpaint Group
‘A chance to build’: Leo Tarkovsky details his move to Fingerpaint Group
Marc Iskowitz
October 5, 2022
10:30 am

The exec brings an extensive holding-company pedigree to the independent agency.

Urica Therapeutics taps Pfizer’s Jay D. Kranzler for CEO post
Urica Therapeutics taps Pfizer’s Jay D. Kranzler for CEO post
Marc Iskowitz
October 3, 2022
2:44 pm

Kranzler, who has been an advisor to Urica, is expanding his role with the biopharma and will manage the development of its gout candidate.

Amylyx ALS drug Relyvrio wins FDA nod, but price raises eyebrows
Amylyx ALS drug Relyvrio wins FDA nod, but price raises eyebrows
Marc Iskowitz
September 30, 2022
3:53 pm

On a call with analysts Friday morning, the company defended the $158,000 price tag and carved out some wiggle room on an earlier withdrawal pledge.

Long-term safety remains a question for Biogen-Eisai’s lecanemab
Long-term safety remains a question for Biogen-Eisai’s lecanemab
Marc Iskowitz
September 30, 2022
10:48 am

The monoclonal antibody produced about the same clinical effect as Aduhelm in a phase 3 trial, yet is being hailed as the next approvable treatment for Alzheimer’s disease. What could go wrong?

Fingerpaint buys med-comms shop Parsons
Fingerpaint buys med-comms shop Parsons
Marc Iskowitz
September 29, 2022
10:07 am

The agency’s latest acquisition marks its second in the past three months.

Why a recommendation to screen adults for anxiety is a double-edged sword
Why a recommendation to screen adults for anxiety is a double-edged sword
Marc Iskowitz
September 23, 2022
1:27 pm

A U.S. task force recommended screening all adults for anxiety. Professionals worry it may worsen access to mental health care.

Boehringer calls on Bernie Williams to take ILD awareness effort into extra innings
Boehringer calls on Bernie Williams to take ILD awareness effort into extra innings
Marc Iskowitz
September 22, 2022
9:00 am

The latest phase of Yankees legend Bernie Williams’ work with BI explores how music may support those living with rare lung conditions.

Bluebird Bio nabs its 2nd gene therapy approval: The $3M Skysona
Bluebird Bio nabs its 2nd gene therapy approval: The $3M Skysona
Marc Iskowitz
September 19, 2022
4:14 pm

Approved for an ultra-rare neurological disease affecting young boys, the drug’s price tops that of previously approved $2.8 million Zynteglo.

Period tracker app Flo turns on ‘anonymous mode.’ Will it ease user privacy concerns?
Period tracker app Flo turns on ‘anonymous mode.’ Will it ease user privacy concerns?
Marc Iskowitz
September 19, 2022
10:54 am

Such measures may not totally shield users of period trackers and fertility apps from post-Roe privacy worries.

Digital downshift: Analyzing the slowdown in pharma’s digital ad-spend growth
Digital downshift: Analyzing the slowdown in pharma’s digital ad-spend growth
Marc Iskowitz
September 16, 2022
11:16 am

‘Reprioritization’ seen in the marketing mix as the industry finds a new post-COVID equilibrium.

  • From Our Partners